Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hernan Carol

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Pediatric Blood & Cancer|July 4, 2012
Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing ProgramHernan Carol, C Patrick Reynolds, Min H Kang, et al.
Cancer Research|June 16, 2016
Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic BirinapantJennifer Richmond, Alissa Robbins, Kathryn Evans, et al.
Pediatric Blood & Cancer|February 9, 2012
Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing programRichard Gorlick, E Anders Kolb, Peter J Houghton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2014
Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing programMalcolm A Smith, C Patrick Reynolds, Min H Kang, et al.
Pediatric Blood & Cancer|September 1, 2010
Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing ProgramE Anders Kolb, Richard Gorlick, Peter J Houghton, et al.
Pediatric Blood & Cancer|October 21, 2011
Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing programMalcolm A Smith, John M Maris, Richard Gorlick, et al.
Pediatric Blood & Cancer|January 23, 2016
Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing ProgramRichard Gorlick, E Anders Kolb, Stephen T Keir, et al.
Pediatric Blood & Cancer|September 22, 2016
Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing programRichard Lock, Hernan Carol, John M Maris, et al.
Pediatric Blood & Cancer|September 30, 2014
Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673Malcolm A Smith, Oliver A Hampton, C Patrick Reynolds, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2015
Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemiaJennifer Richmond, Hernan Carol, Kathryn Evans, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Pediatric Blood & Cancer|July 4, 2012
Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing ProgramHernan Carol, C Patrick Reynolds, Min H Kang, et al.
Cancer Research|June 16, 2016
Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic BirinapantJennifer Richmond, Alissa Robbins, Kathryn Evans, et al.
Pediatric Blood & Cancer|February 9, 2012
Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing programRichard Gorlick, E Anders Kolb, Peter J Houghton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2014
Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing programMalcolm A Smith, C Patrick Reynolds, Min H Kang, et al.
Pediatric Blood & Cancer|September 1, 2010
Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing ProgramE Anders Kolb, Richard Gorlick, Peter J Houghton, et al.
Pediatric Blood & Cancer|October 21, 2011
Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing programMalcolm A Smith, John M Maris, Richard Gorlick, et al.
Pediatric Blood & Cancer|January 23, 2016
Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing ProgramRichard Gorlick, E Anders Kolb, Stephen T Keir, et al.
Pediatric Blood & Cancer|September 22, 2016
Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing programRichard Lock, Hernan Carol, John M Maris, et al.
Pediatric Blood & Cancer|September 30, 2014
Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673Malcolm A Smith, Oliver A Hampton, C Patrick Reynolds, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2015
Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemiaJennifer Richmond, Hernan Carol, Kathryn Evans, et al.
Pageof 7